Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor

A pharmaceutical composition comprising a SGLT2 inhibitor selected from the group consisting of

• (1) Dapagliflozin;
• (2) Remogliflozin or Remogliflozin etabonate;
• (3) Sergliflozin or Sergliflozin etabonate;
• (4) 1-Chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethyl-benzyl)-benzene;
• (5) (1S)-1,5-Anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol;
• (6) (1S)-1,5-Anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol;
• (7) Thiophen derivative of the formula (7-1)
• wherein R denotes methoxy or trifluoromethoxy;
• (8) 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene;
• (9) Spiroketal derivative of the formula (9-1):
• wherein R denotes methoxy, trifluoromethoxy, ethoxy, ethyl, isopropyl or tert. butyl;
• or a pharmaceutically acceptable salt, hydrate or solvate thereof;
• in combination with a DPP IV inhibitor of formula (I)
• or formula (II)
• or formula (III)
• or formula (IV)
• wherein R1 denotes ([1,5]naphthyridin-2-yl)methyl, (quinazolin-2-yl)methyl, (quinoxalin-6-yl)methyl, (4-methyl-quinazolin-2-yl)methyl, 2-cyano-benzyl, (3-cyano-quinolin-2-yl)methyl, (3-cyano-pyridin-2-yl)methyl, (4-methyl-pyrimidin-2-yl)methyl, or (4,6-dimethyl-pyrimidin-2-yl)methyl and R2 denotes 3-(R)-amino-piperidin-1-yl, (2-amino-2-methyl-propyl)-methylamino or (2-(S)-amino-propyl)-methylamino, or its pharmaceutically acceptable salt.